Medical Editor: John P. Cunha, DO, FACOEP
Cinobac (cinoxacin) is an antibiotic used to treat initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: Escherichia coli Proteus mirabilis Proteus vulgaris Klebsiella species (including K.pneumoniae) and Enterobacter species. The brand name Cinobac is discontinued but generic versions may be available. Common side effects of Cinobac (cinoxacin) include:
- abdominal pain i
- tingling sensation
- sensitivity of eyes to light
- burning sensation in the groin area,
- and ringing in the ears
The usual adult dosage of Cinobac for the treatment of urinary tract infections is 1 g daily, administered orally in 2 or 4 divided doses (500 mg twice daily or 250 mg four times daily respectively) for 7 to 14 days. Cinobac may interact with theophylline, caffeine, antacids or sucralfate, products containing iron, multivitamins containing zinc, didanosine, oral anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclosporine. Tell your doctor all medications and supplements you use. During pregnancy, Cinobac should be used only if prescribed. It is unknown if this drug passes into breast milk. Similar drugs pass into breast milk. Consult your doctor before breastfeeding.
Our Cinobac (cinoxacin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In clinical studies involving 1,118 patients, the following adverse effects were considered to be related to cinoxacin therapy:
Gastrointestinal: Nausea was reported most commonly and occurred in less than 3 in 100 patients. Other side effects, occurring less frequently (1 in 100), were anorexia, vomiting, abdominal cramps/pain, perverse taste, and diarrhea.
Central Nervous System: The most frequent side effects were headache and dizziness, reported by 1 in 100 patients. Other adverse reactions possibly related to Cinobac (cinoxacin) include insomnia, drowsiness, tingling sensation, perineal burning, photophobia, and tinnitus. These were reported by less than 1 in 100 patients.
Hypersensitivity: Rash, urticaria, pruritus, edema, angioedema, and eosinophilia were reported by less than 3 in 100 patients. Rare cases of anaphylactic reactions have been reported. Toxic epidermal necrolysis has been reported very rarely. Erythema multiforme and Stevens-Johnson syndrome have been reported with cinoxacin and other drugs in this class.
Hematologic: Rare reports of thrombocytopenia.
Laboratory values reported to be abnormal were, in descending order of frequency, elevation of BUN (1 in 100), AST (SGOT), ALT (SGPT), serum creatinine, and alkaline phosphatase; and reduction in hematocrit/hemoglobin (each less than 1 in 100).
Although not observed in the 1,118 patients treated with cinoxacin the following side effects have been reported for other drugs in the same pharmacologically active and chemically related class: restlessness nervousness, change in color perception, difficulty in focusing, decrease in visual acuity, double vision, weakness, constipation, erythema and bullae feelings of disorientation or agitation or acute anxiety, palpitation, soreness of the gums, joint stiffness, swelling of the extremities, and toxic psychosis or convulsions (rare). All adverse reactions observed with drugs in this class were reversible.
The most frequently reported adverse events in post marketing surveillance of cinoxacin have been rash and anaphylactic reactions. Other frequently reported reactions have been pruritus, urticaria, allergic reactions, nausea, abdominal pain, and headache.
Read the entire FDA prescribing information for Cinobac (Cinoxacin)
© Cinobac Patient Information is supplied by Cerner Multum, Inc. and Cinobac Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.